RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy
- 20 April 2006
- journal article
- Published by Springer Nature in Gene Therapy
- Vol. 13 (18) , 1360-1370
- https://doi.org/10.1038/sj.gt.3302778
Abstract
RNA interference (RNAi) entails the potential for novel therapeutic strategies through the silencing of disease-causing genes in vivo. However, recent studies have raised an issue regarding applicable routes of administration for small interfering RNA (siRNA) molecules as therapeutics. In this study, we demonstrate that liposomally formulated siRNA molecules, the so-called siRNA-lipoplexes, but not naked siRNAs, are delivered to the tumor endothelial cells in vivo by microscopy. In addition, functional intracellular delivery of formulated siRNA targeting the tumor suppressor PTEN is shown in endothelial cells of the liver and tumor. Finally, the therapeutic potential of systemically administered siRNACD31-lipoplexes is established by inhibition of tumor growth in two different xenograft mouse models. Our findings corroborate the applicability of this liposomal siRNA delivery technology for inducing RNAi to modulate gene expression levels in angiogenesis-dependent processes. In addition, our results advocate CD31 as a promising therapeutic target for antiangiogenic intervention. Therefore, our study provides a basis for the development of antiangiogenic cancer therapies based on RNAi.Keywords
This publication has 47 references indexed in Scilit:
- Dicing and slicingFEBS Letters, 2005
- The therapeutic potential of RNA interferenceFEBS Letters, 2005
- RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivoGene Therapy, 2004
- Silencing of hdm2 oncogene by siRNA inhibits p53-dependent human breast cancerCancer Gene Therapy, 2004
- Intravenous RNA Interference Gene Therapy Targeting the Human Epidermal Growth Factor Receptor Prolongs Survival in Intracranial Brain CancerClinical Cancer Research, 2004
- RETRACTED ARTICLE: EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinomaOncogene, 2004
- Killing the messenger: short RNAs that silence gene expressionNature Reviews Molecular Cell Biology, 2003
- The biology of VEGF and its receptorsNature Medicine, 2003
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTENCell, 1998